Literature DB >> 8098243

Comparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension.

G Simon1, M L Johnson.   

Abstract

dl-nebivolol is a new, chemically unique, selective beta 1-adrenoceptor antagonist, without sympathomimetic activity. In the present study, the antihypertensive and negative chronotropic effects of 5 and 10 mg once-daily nebivolol were compared to those of 50 and 100 mg once-daily atenolol in 25 white, male subjects with essential hypertension, using a double-blind, crossover design, and a parallel placebo-treated group of subjects (N = 7). 24 hours after dosing, sitting and standing diastolic and systolic blood pressures and heart rates (at rest and during submaximal exercise) were reduced to the same extent by nebivolol and atenolol. On a weight-for-weight basis, nebivolol is ten times more potent than atenolol. Nebivolol and atenolol also reduced 1-hour ambulatory plasma renin activity. Once-daily nebivolol is an effective antihypertensive beta-adrenoceptor antagonist.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098243     DOI: 10.3109/10641969309041625

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  5 in total

1.  Effects of nebivolol on artery hypertension--multicentre study Bosnia and Herzegovina.

Authors:  Zumreta Kusljugić; Katarina Divković; Fahir Baraković; Elnur Smajić; Amila Arslanagić; Mustafa Hadziomerović; Emir Fazlibegović; Zlatko Midzić; Enes Abdović; Milenko Krneta; Radenko Celik; Hajro Basić; Bajro Avdić; Adnan Delić; Amra Macić-Dzanković; Nedzad Keco; Hajra Boskailo
Journal:  Bosn J Basic Med Sci       Date:  2005-02       Impact factor: 3.363

Review 2.  Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine.

Authors:  David Feldman; Terry S Elton; Doron M Menachemi; Randy K Wexler
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

Review 3.  Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation.

Authors:  Robert Weiss
Journal:  Vasc Health Risk Manag       Date:  2006

Review 4.  Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data.

Authors:  Thomas D Giles; John R Cockcroft; Bertram Pitt; Abhijeet Jakate; Harold M Wright
Journal:  J Hypertens       Date:  2017-09       Impact factor: 4.844

Review 5.  Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.

Authors:  Waleed AlHabeeb; Sanaa Mrabeti; Ahmed Adel Ibrahim Abdelsalam
Journal:  Cardiovasc Drugs Ther       Date:  2021-06-09       Impact factor: 3.947

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.